These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38594809)

  • 1. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
    Wei W; Blaha O; Esserman D; Zelterman D; Kane M; Liu R; Lin J
    Stat Med; 2024 May; 43(12):2439-2451. PubMed ID: 38594809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-supervised mixture multi-source exchangeability model for leveraging real-world data in clinical trials.
    Haine LMF; Murry TA; Nahra R; Touloumi G; Fernández-Cruz E; Petoumenos K; Koopmeiners JS
    Biostatistics; 2024 Jul; 25(3):617-632. PubMed ID: 37697901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing shared internal control arms and historical information in small-sized platform clinical trials.
    Jiao F; Tu W; Jimenez S; Crentsil V; Chen YF
    J Biopharm Stat; 2019; 29(5):845-859. PubMed ID: 31462131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian adaptive design for covariate-adaptive historical control information borrowing.
    Jin H; Kim MO; Scheffler A; Jiang F
    Stat Med; 2023 Dec; 42(29):5338-5352. PubMed ID: 37750361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian local exchangeability design for phase II basket trials.
    Liu Y; Kane M; Esserman D; Blaha O; Zelterman D; Wei W
    Stat Med; 2022 Sep; 41(22):4367-4384. PubMed ID: 35777367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
    Bi D; Liu M; Lin J; Liu R
    Stat Med; 2023 Dec; 42(30):5708-5722. PubMed ID: 37858287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials.
    Su L; Chen X; Zhang J; Yan F
    JCO Precis Oncol; 2022 Mar; 6():e2100394. PubMed ID: 35263169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A group-sequential randomized trial design utilizing supplemental trial data.
    Kotalik A; Vock DM; Hobbs BP; Koopmeiners JS
    Stat Med; 2022 Feb; 41(4):698-718. PubMed ID: 34755388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
    Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
    Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flexible Bayesian framework for individualized inference via adaptive borrowing.
    Ji Z; Wolfson J
    Biostatistics; 2023 Jul; 24(3):669-685. PubMed ID: 35024790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calibrated dynamic borrowing using capping priors.
    Ling SX; Hobbs BP; Kaizer AM; Koopmeiners JS
    J Biopharm Stat; 2021 Nov; 31(6):852-867. PubMed ID: 35129422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases.
    Sebastien B
    J Pharmacokinet Pharmacodyn; 2023 Dec; 50(6):495-499. PubMed ID: 37148459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
    Wang X; Suttner L; Jemielita T; Li X
    J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
    Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
    Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified power prior with multiple historical trials for binary endpoints.
    Banbeta A; van Rosmalen J; Dejardin D; Lesaffre E
    Stat Med; 2019 Mar; 38(7):1147-1169. PubMed ID: 30360016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.